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Abstract
We examined whether specific input data and assumptions explain outcome differences in
otherwise comparable health impact assessment models. Seven population health models
estimating the impact of salt reduction on morbidity and mortality in western populations
were compared on four sets of key features, their underlying assumptions and input data.
Next, assumptions and input data were varied one by one in a default approach (the
DYNAMO-HIA model) to examine how it influences the estimated health impact. Major dif-
ferences in outcome were related to the size and shape of the dose-response relation
between salt and blood pressure and blood pressure and disease. Modifying the effect sizes
in the salt to health association resulted in the largest change in health impact estimates
(33% lower), whereas other changes had less influence. Differences in health impact
assessment model structure and input data may affect the health impact estimate. There-
fore, clearly defined assumptions and transparent reporting for different models is crucial.
However, the estimated impact of salt reduction was substantial in all of the models used,
emphasizing the need for public health actions.
Introduction
The World Health Organization (WHO) recently estimated that dietary risk factors accounted
for 11.3 million deaths and 241.4 million disability-adjusted life years (DALYs) [1], with high
salt intake being a major contributor [2]. The WHO has set a target to reduce population salt
intake by 30%, aiming at an average of 5 gram per day, by 2025 [3]. Sodium reduction in pro-
cessed foods, and raising awareness of consumers on salt reduction and monitoring salt con-
sumption in populations and food reformulations are the primary interventions to reduce the
level of salt intake [4]. For several countries, the expected health gain (e.g. averted morbidity or
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DALYs) related to salt reduction have been calculated [5–9]. These studies used different
approaches to quantify the health impact of salt reduction. Differences in modelling ap-
proaches can affect the estimated number of incident cases of disease averted or the number of
deaths postponed. To illustrate, Coxson et al demonstrated that a 3-gram lower salt intake
could avert 280,000 deaths in the USA using a dynamic-state transition model that estimated
salt reduction on blood pressure and subsequently on mortality, but this number almost dou-
bled (500,000 deaths) when a direct effect on mortality was estimated using relative risks from
a post-hoc observational analysis of an randomized controlled trial of sodium reduction [8]. In
otherwise comparable quantitative health impact assessment (HIA) models, these estimates
may also lead to heterogeneity in estimated health outcomes. For example, Scarborough et al
observed that applying the assumptions of the CHD policy model leads to a calculated 8 to
16% of CVD deaths being postponed, while a similar analysis using the PRIME model (previ-
ously the DIETRON model) suggested a postponement of 4 to 6% [10]. Such heterogeneities
may be due to variation in underlying assumptions on the salt intake to health effect associa-
tion or due to intrinsic factors of the models. Therefore, insight in the underlying model struc-
tures, assumptions and (demographic) input data used is essential to interpret and compare
the outcomes of population health models.
The objective of the present study is to gain insight in how differences in various HIA mod-
els may result in heterogeneity in health impact estimates. We first identified eight models
used to calculate the health impact of salt reduction, and describe their differences. In a follow-
ing step we used the population health modelling tool DYNAMO-HIA to estimate to what
extent the variation in the modelling assumptions and (demographic) input data used in these
models affect the outcome of health impact estimates.
Materials and methods
Selection of models
We searched PubMed for research papers that calculated the long-term health impact of salt
reduction published until August 2013, using ‘salt reduction’, ‘health impact assessment’ and
‘modelling study’ as key words. We limited our search to five models: CHD policy model [8,
11]; PRIME model [10]; Proportional Multistate Life-Table (PMLT) [7]; Global burden of dis-
ease (GBD) [2] and RIVM-CDM [12].
We also identified three additional salt reduction models that fulfilled the above mentioned
criteria, but at the time of our search the results had not yet been published (IMPACT model
[13], DYNAMO-HIA model [14] and UK Health Forum model. Since the UK Health Forum
Model on salt reduction is not yet published in a peer-reviewed journal, our present analyses
concern seven models.
Identification of model features
We identified four key features of the models related to the aim of the study, the characteristics
of the quantitative impact assessment model used and the output obtained (Fig 1). In our view
the most relevant data needed in the model and assumptions that need to be made are clus-
tered in seven boxes in Fig 1 for each feature. In Table 1 we described for each model which
(demographic) input data were used and how assumptions were worked out.
Selection of input data or assumptions for modelling exercise
We selected the DYNAMO-HIA model to calculate the effect of the modification of the
(demographic) input data and assumptions on the health impact estimates. A detailed
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description of the model can be found elsewhere [14, 25]. We identified those input data and
assumptions within sets of key features that differed between the selected models. Subse-
quently, we evaluated which input data and assumptions could be modified in the DYNA-
MO-HIA approach. The ten selected input data and assumptions are marked bold in Fig 1.
Some other assumptions or (demographic) input data differed between the selected models,
but those assumptions are too closely related to the model structure or could not be modulated
in another modelling setting. For example, a model may provide either dynamic or static pro-
jections. Static models have no dimension of time, while dynamic models make it possible to
estimate changes over time, and as such take into account competing risks. Such a structure
cannot be modified. Therefore such differences were not examined in the present analysis. We
also choose not to model the impact of changing any input data or assumptions related to the
characteristic “Population salt intake and scenario development”.
Varying modifiable input data and assumptions using DYNAMO-HIA
The selected assumptions were modified so that new input parameters were obtained. The
shape and the source of the dose-response association for salt reduction to blood pressure
Fig 1. Four key features and its underlying assumptions and input data of the modelling approaches of salt reduction.
https://doi.org/10.1371/journal.pone.0186760.g001
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Table 1. Comparison of main model features of the models that calculated health impact of salt intake reduction.
Modelling
approaches
CHD policy model
[8, 11]
Proportional
multistate life
table [7]
RIVM-CDM [12] PRIME Model
[10]
IMPACT model [13] Global burden
of disease [15]
DYNAMO-HIA
[14]
Population salt intake & scenario development
Goal 1 g/d reduction; 2
g/d reduction; 3 g/d
reduction
4 specific
interventions
2 specific
interventions
and goal intake
to 6 g/d
Goal: 6 g/d 2–20% intake
reduction due to
specific
interventions
Theoretical
minimum risk
exposure
30% reduction;
Goal: 5 g/d
Lag times in
scenario
Gradual reduction
in sensitivity
analyses
No No No 1 year after
baseline
No No
Salt intake
levels
Population level &
population shift
Population level &
population shift
Individual level
and individual
shift
Population level
& population
shift
Population level Population level Population level
and shift
General input data of model
Population of
model
35-80y >30y >20y <75y Total population Total population >18y
Diseases
included
Cardiac arrest, MI,
CHD and stroke
IHD, stroke AMI, CVA, CHF IHD, stroke,
stomach cancer
AMI, post AMI, HF,
angina, post
revascularisation
Stomach
cancer, IHD,
strokes, several
other CVD,
chronic kidney
disease
IHD, stroke
Disease
sources (year)
Prevalence: Survey
Incidence: hospital
register, MI registry
(2000) from USA
Australian burden
of disease (<2008
and trends to 2020)
Dutch GP and
Hospital
register (2007)
UK cause-
specific mortality
(2007)
Hospital statistics,
MI audit project,
GP-register from
UK (1993–2010 and
predicted to 2020)
DISMOD-MR(3)
(2010)
Dutch GP
registry (2003)
Main model structures
Effect of salt
on CVD/other
disease
Indirect Indirect Indirect Indirect Indirect Indirect
(SBP-CVD) and
direct (stomach
cancer)
Indirect
Projections Dynamic Dynamic Dynamic Static Static Static Dynamic
Risk factor
distribution
Categorical Continuous Continuous
(salt);
Categorical
(SBP)
Continuous Continuous Continuous Categorical
(salt) and
continuous
(SBP)
Other risk
factors
Yes, multiplicative Not used (but
optional)
Not used (but
optional)
Yes,
multiplicative
No No No
Modelling dose-response of salt intake on blood pressure
Source of
dose-
response
association
He & MacGregor,
2004 [16] for low
risk estimate and
[17, 18] for high risk
estimates
Law et al, 1991 [19] He &
MacGregor,
2004 [16]
He &
MacGregor,
2008 [20]
He & MacGregor,
2004 [16]
Own meta-
analysis based
on He and
MacGregor
2008 and
Graudal et al,
2011 [21]
He &
MacGregor,
2004 [16]
Shape Linear Exponential Exponential Linear Linear Linear Exponential
Role of
hypertension
By hypertension;
>65 years is
hypertension
Depends on SBP
level
Depends on
SBP level
In
normotensives
only, age-
dependent from
DASH trial
By hypertension By age Depends on
SBP level
Medication
use
Medication is
treated similar as
hypertension
Ignored Ignored Ignored Ignored Ignored Ignored
(Continued )
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Table 1. (Continued)
Modelling
approaches
CHD policy model
[8, 11]
Proportional
multistate life
table [7]
RIVM-CDM [12] PRIME Model
[10]
IMPACT model [13] Global burden
of disease [15]
DYNAMO-HIA
[14]
Change in risk
factor during
modelling
period
Unchanged Unchanged Unchanged N/A N/A N/A Unchanged
Modelling dose-response of blood pressure to CVD
Source of
dose-
response
association
Framingham risk
scores [22],
Prospective
Studies
Collaboration [23]
Prospective
Studies
Collaboration
and own meta-
analysis (CHF)
[23]
Prospective
Studies
Collaboration
[23]
INTERHEART, [24] Prospective
Studies
Collaboration
[23] for CVD
Prospective
Studies
Collaboration
[23]
Attenuation
correction
No Yes Yes No No No Yes
Age-
dependent
No (age effect not
significant)
Yes Yes Yes Yes Yes Yes
Recurrence of
disease
Ignored The lag option is
based on WHO
assumption of full
reversal of stroke
risk after 3 years,
and two-thirds
reversal of heart
disease risk after 3
years, with the
remaining heart
disease risk
reversed over
seven subsequent
years.
Ignored Ignored Ignored Ignored Ignored
Modelling effect of CVD to mortality
Direct or
indirect
Indirect (including
direct fatality)
Indirect Indirect Direct Direct Direct Indirect
Competing
risks
Yes Yes Yes N/A N/A N/A Yes
Source
mortality from
disease data
Framingham
adjusted for trends
in risk factors and
calibrated to
national cause of
death data; specific
data sources
separating out over
categories
Australian burden
of disease
Record linkage
of Dutch GP
registry and
hospital register
N/A Median survival,
estimated 2020
mortality
DISMOD-MR GP registry
Mortality
depends on
salt intake/
SBP before
diseases
Yes No No N/A N/A N/A No
Mortality
depends on
salt intake/
SBP after
disease
No No No N/A N/A N/A No
Diseases
mutual
exclusive
Partly No (independent) No
(independent)
N/A Yes One at the time No
(independent)
(Continued )
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were combined into a single input parameter. We also adapted input data, such as the age of
the population, disease sources and time frame of the simulation. In an additional simulation
we mirrored the CHD policy model approach [11] in DYNAMO-HIA, using the following
input 1) age range of the population from 35 to 80 years; 2) relative risks for the salt to SBP
relation from a meta-analysis of randomized controlled trials; 3) change of mean blood pres-
sure levels within categories; 4) relative risks for the BP to CVD relation from the Framingham
Study and 5) ‘other cause mortality’ (that is, other causes than the modelled diseases IHD and
stroke) depending on current blood pressure levels. We used DYNAMO-HIA version 2.07. In
all situations, we simulated the health impact of a 3-gram salt reduction for the Dutch popula-
tion in a closed cohort. The default situation of the DYNAMO-HIA approach and the alterna-
tive simulations are presented in Table 2. The alternative simulations were each compared
with the default situation. For each simulation, we report the effect on the incidence of stroke
and ischemic heart disease (IHD). We also estimated the effect on the life expectancy (LE) for
a 60-year old individual. An overview of relative risks used in the calculations is presented in
the supplementary information.
Results
Model features and its underlying assumptions and input data
Table 1 shows the assumptions and input data of the main model features for all seven models.
With respect to the population salt intake and scenario development, we observed that all
models simulated a salt reduction scenario: estimating the effect of an intervention or a fixed
target. In the scenarios, no lag time of the intervention scenario was assumed, except for the
CHD policy and IMPACT model, and a change in salt intake at population level was estimated,
except for RIVM-CDM where individual shifts in salt intake were used. With respect to the
general input data of the model, the age range of the population exposed to the intervention
also differed. All models estimated the effect of salt reduction on CVD mediated by SBP.
GBD and PRIME included diseases other than CVD. Prevalence and incidence data of the dis-
eases at the start of the simulation, necessary as input for the models, were based on country-
specific registries and databases. Concerning the main model structures, we identified four
dynamic (CHD policy model, RIVM-CDM, DYNAMO-HIA and PMSLT) and three static
models (PRIME, IMPACT and GBD). Salt intake and/or systolic blood pressure (SBP) were
divided into categories in the CHD policy model, RIVM-CDM and DYNAMO-HIA, but were
considered continuous in the other models. The effect of SBP changes over categories was
approached differently between RIVM-CDM and the CHD policy model. In RIVM-CDM, the
Table 1. (Continued)
Modelling
approaches
CHD policy model
[8, 11]
Proportional
multistate life
table [7]
RIVM-CDM [12] PRIME Model
[10]
IMPACT model [13] Global burden
of disease [15]
DYNAMO-HIA
[14]
Reported outcomes
Indicator Incidence, all-
cause mortality and
QALYs
DALY, lifetime
mortality and
morbidity
LYG, DALY,
incidence and
mortality
Cause-specific
mortality
LYG, DPP DALY (YLL,
YLD)
Prevalence,
mortality and
DALYs
Period of
simulation
10y Lifetime 20y N/A 10y N/A 20y
LYG: life years gained; DPP: deaths prevented or postponed; QALY: quality adjusted life years; DALY: disability adjusted life years; YLD: years lived with
disease; YLL: years lived lost
https://doi.org/10.1371/journal.pone.0186760.t001
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prevalence of the population within the SBP categories changed. In the CHD policy model the
mean SBP within each SBP was decreased within each SBP category.
Five HIA models derived the salt-blood pressure relation from the same meta-analysis of
RCTs [16] and one (PMSLT) from a meta-analysis of observational studies [19]. The CHD pol-
icy approach obtained two dose-response relationships from two types of studies. The first is
based on the meta-analysis of randomized controlled trials [16], and a second is based on data
from clinical trials [17, 18]. The dose-response relation obtained from the similar publication
of He and MacGregor [16] could be interpreted as a separate linear dose-response relations for
normotensive and hypertensive subjects (CHD Policy model, GBD, PRIME and IMPACT), or
could be constructed in an exponential dose-response relationship that depended on blood
pressure (PMLST, RIVM-CDM and DYNAMO-HIA). The association between blood pres-
sure and CVD was derived in most models (RIVM-CDM, PMSLT, DYNAMO-HIA, PRIME
and GBD) from the Prospective Studies Collaboration [23]. RIVM-CDM, PMLST and DYNA-
MO-HIA adjusted the variance of the measured SBP levels of the population for the within-
subject variability (attenuation correction). PRIME and GBD used only the population-aver-
age SBP levels and not its variance. The CHD policy model and the IMPACT model obtained
the effect size of the SBP to CVD morbidity relationship from specific cohort studies, namely
the Framingham Cohort Study and the INTERHEART Study [22] [24].
A combination of disease incidence and mortality and integrative measures (such as
DALYs) are mostly reported as outcome measure. The period of simulation varies between 10
years (CHD policy model and IMPACT model) to lifetime (PMSLT).
Table 2. Overview of the assumptions and input data within the DYNAMO-HIA approach (default situation) and its modifications in the alternative
simulations.
Features Default situation Alternations compared to default situation
General input of model
Population of model > 18 years 35–80 years
Disease sources GP registries, 2001 GP registries and hospital registration from 2010
Main model structures
Risk factor distribution Categorical for salt intake (per 2 g salt), but
continuous blood pressure distribution
Categorical for salt intake (per 2 g salt), and categorical
for blood pressure (per 20 mmHg)
Changing prevalence of population in SBP categories
(RIVM-CDM approach)
Change of mean blood pressure in SBP categories (CHD
policy approach)
Modelling dose-response of salt reduction to blood pressure
Shape and source of dose-response
association
He and MacGregor, 2004; Exponential Law et al, 1991;Linear
Modelling dose-response of blood pressure to CVD
Source of dose-response association Prospective Studies Collaboration, 2002, age-
specific
Framingham Risk Estimates, unadjusted for age
Attenuation correction Measured blood pressure adjusted for within-subject
variation
Measured blood pressure
Age-dependent Yes No age-dependency using Framingham risk estimates
Modelling effect of CVD to mortality
Other cause1 of death mortality
depends on salt intake/SBP
No Yes
Reported outcomes
Period of simulation 10 years Extended to 20 years
Extended to 50 years
1Other then stroke and IHD
https://doi.org/10.1371/journal.pone.0186760.t002
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Effect of the modifications of input data or assumptions on estimated
health impact
Table 3 shows the various estimates of the impact of a 3-gram salt reduction (using the DYNA-
MO-HIA model) for the population aged 18 years and older in the Netherlands applying six
alternative assumptions and four variations of input data. In the default situation, after 10
years, a 3 gram salt reduction resulted in a 10.5% reduction (N = 30,800) in stroke incidence
Table 3. Effect of eight modifiable assumptions and input data on the health impact estimate of a 3 gram salt reduction using the DYNAMO-HIA
model.
CVA incidence IHD incidence
Baseline 3 g/d salt
intake
reduction
Absolute
difference
% reduction (%
difference with
default
approach)
Baseline 3 g/d salt
intake
reduction
Absolute
difference
% reduction (%
difference with
default
approach)
Default1 292,700 261,900 30,800 10.5 483,600 445,500 38,100 7.9
General input of the model
Population of
model
35–80 y 253,500 225,000 28,500 11.2 (+6%) 445,400 409,800 35,600 8.0 (1%)
Disease
sources
CVD data from
2010
275,200 246,300 28,900 10.5 (0%) 528,000 487,000 41,000 7.8 (-1%)
Main model structures
Risk factor
distribution
Change in
prevalence in
categories
290,800 269,100 21,700 7.2 (-31%) 482,100 456,400 25,700 5.4 (-32%)
Change in mean
SBP in categories
290,800 261,300 29,500 10.1 (-4%) 482,000 444,400 37,600 7.8 (-1%)
Modelling effect of salt reduction in blood pressure
Salt intake–
SBP
Linear
association, with
RR from Law,
1991
293,400 256,200 37,300 12.7 (+19%) 483,700 437,400 46,300 9.6 (+22%)
Modelling effect of blood pressure on CVD
SBP-CVD RR from
Framingham
292,900 270,900 22,000 7.5 (-33%) 483,600 460,200 23,400 4.8 (-40%)
Attenuation
correction
No correction
usual SBP
292,700 258,400 34,300 11.7 (+11%) 483,600 442,600 41,000 8.5 (+8%)
Modelling effect of CVD on mortality
Mortality also
depends on
SBP directly2
Other cause of
death mortality
depends on salt
intake/SBP
292,700 261,400 31,300 10.7 (+2%) 483,600 444,600 39,000 8.1 (+3%)
Reported outcomes
Period of
simulation
Extended to 20 y 652,400 586,400 66,000 10.1 (-4%) 1,066,700 986,500 80,200 7.5 (-5%)
Extended to 50 y 1,889,200 1,717,800 171,400 9.0 (-14%) 2,808,100 2,621,974 186,200 6.6 (-16%)
Combined approach
Similar to CHD
policy model
252,900 233,300 16,900 7.8 (-26%) 445,200 422,900 22,300 5.0 (-37%)
1 default situation: 10-year period, population aged >18 years and older, correction for RDR. RR salt intake and SBP from He and MacGregor et al 2004
(exponential), RR SBP-CVD Lewington et al, 2002, measured SBP corrected with regression dilution ratio
2The pathway from SBP to mortality in this model is both through the “indirect” effect of SBP increasing stroke and IHD incidence, and through a direct effect
on mortality from other causes
https://doi.org/10.1371/journal.pone.0186760.t003
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and a 7.9% reduction in IHD incidence (N = 38,100). The gain in LE was 0.16 years for men
and 0.14 years for women (Fig 2).
The largest changes in health impact estimates were observed when risk estimates in the
dose-responses association were changed. In the simulation using risk estimates for the rela-
tion between blood pressure and diseases from the Framingham Cohort Study, the absolute
numbers as well as the percentage reduction of the estimated disease incidence was consider-
ably lower compared with the default situation (7.5% (N = 22,000) reduction for stroke and
4.8% (N = 23,400) for IHD; Table 3). This means a 33% lower estimate for stroke and a 40%
lower estimate for IHD compared with the default situation. The health impact estimates were
higher if the linear association between salt intake and blood pressure taken from the study of
Law were incorporated in the model (lower estimate of 12.5% (N = 36,500) for stroke and
9.6% (N = 46,300) for IHD). This means a 19% higher estimate for stroke and a 22% higher
estimate for IHD compared to the default situation.
Other substantial differences with the default simulation occurred when the prevalence of
the population in each SBP categories shifted as a consequence of salt reduction (31% lower
estimate for stroke and 32% lower estimate for IHD as compared to the default situation; see
Table 3). Other changes have a small impact, such as no correction for usual blood pressure.
Extending the calculations to 20 or to 59 years does not have an effect on percentage change,
but the absolute number of incident cases is much higher when the calculations are extended
to 20 or to 50 years. The combined approach with modifications similar to the CHD policy
Fig 2. Gain in life expectancy for men and women aged 60 between 3 gram salt reduction and current salt intake for the various simulations.
https://doi.org/10.1371/journal.pone.0186760.g002
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model led to a stroke reduction of 7.8% and to an IHD reduction of 5.0%. This means a 26%
lower estimate for stroke and a 37% decreased estimate for IHD compared to the default
situation.
Gain in life expectancy (Fig 2) followed a similar trend as the results in Table 3.
Discussion
Our overview of selected HIA models of salt reduction showed that despite the many differ-
ences between the models, there are important similarities. All studies examined the effect of
salt intake on CVD as mediated by SBP, with substantial projected health gains (7.2% to 12.7%
for stroke and 4.8% to 9.6% for IHD). Differences in assumptions between HIA models mainly
concerned the strength of the relationships between salt intake and SBP, and between SBP and
disease occurrence. In addition, we observed that an association obtained from literature
could be interpreted differently in the modelling exercise. The models also differed in intrinsic
model structures, such as categorization of salt intake and/or blood pressure levels and
dynamic versus static approach.
In this study, we assessed to what extent model input data and assumptions may determine
health impact estimates using a standard dynamic model (DYNAMO-HIA). In the default sce-
nario, a 3 gram salt reduction reduced the incidence of stroke by 10.5% and the incidence of
IHD by 7.9%, in the Dutch population over a period of 10 years. Changing the assumptions
relating to the association between salt intake and blood pressure and between blood pressure
and CVD changed the health impact estimates substantially. Changing the relative risks of
blood pressure on CVD reduced the incidence by 33% for stroke and 40% for IHD. After this,
using blood pressure in categories, and allowing salt intake change the proportion of the popu-
lation in each category (reduction of HIA estimate by 27% for stroke and by 18% for IHD)
appeared to have the most effect on the incident cases. Effects of changes in the input data had
less effect; however, extending the time frame of the calculations had a large impact on the
absolute number of incident cases.
This is the first study that systematically compared various indirect and complex health
modelling approaches for salt reduction based on four sets of key model features and their
underlying assumptions and input data. Some limitations of the study need to be addressed.
First, due to the selection of predefined key elements other potential differences, such as dis-
tinctions in subgroups, have not been taken into account. Second, we selected the DYNAMO-
HIA model to quantify only for the Dutch population. The estimated differences in the alter-
native simulations may vary if this exercise is replicated in other models or in other popula-
tions. Finally, we only varied a limited set of input data and assumptions in DYNAMO-HIA
model, and thus we cannot quantify the impact of remaining differences, such as the allowance
of competing risks or using a static modelling approach. The potential difference between
dynamic and static models was not assessed, as it was considered an un-adjustable, intrinsic
aspect of the HIA models. However, we do assume that dynamic models are more adequate to
estimate future health gain as they take into account selective mortality, ageing and competing
risks.
In the present study, the health impact estimates changed when input data and assumptions
were replaced by alternative input data or assumptions. Three assumptions or alternative
input data are the most influential on the relative and absolute outcome of the health impact
assessment: the sources of relative risks used in the blood pressure to health association, the
dose-response between salt intake and blood pressure and the distribution of risk factors.
Because of the importance of the effect of the relative risk on the outcome, it is important that
the source is obtained from good quality, prospective studies. This study showed that using
Identification of differences in health impact modelling of salt reduction
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categorical risk factor distributions seemed to reduce the sensitivity of the model to changes in
salt intake. This is probably due to the fact that this modelling approach lowers blood pressure
in all subjects lowering salt intake will decrease blood pressure in all subjects, but only a few
subjects will shift to a lower blood pressure category and thereby will have a lower risk of devel-
oping CVD.
In general, uncertainty analyses show how the health impact estimate depends on the
underlying assumptions and (demographic) input data within a single HIA model and is
therefore helpful to identify the range of the expected effect. However, uncertainty analyses are
often only applied to a limited set of model assumptions or (demographic) input data, for
example the relative risks (parametric uncertainty). The present study showed that also intrin-
sic model structures and (demographic) input data contribute to the variation in the health
impact estimates (structural uncertainty), but is rarely assessed in modelling studies. There-
fore, there is a clear need for transparency in HIA models, if necessary in a technical appendix,
where transparency refers to the clear description of the model structures and (demographic)
input data used, and also to describe the full range of uncertainty assessed by models. Our
analysis showed that it is important to develop standard reporting guidelines for the field of
non-communicable disease scenario modelling.
Comparing the variation in outcomes from substituting input data or assumptions in a
model one by one was informative to identify the main assumptions that could contribute to
the heterogeneity in the outcomes of published studies. In practice, HIA models vary in several
underlying assumptions. Mirroring our approach to the approach used by the CHD policy
model resulted in an impact estimate higher than the estimate of using the CHD policy model
itself (for example, stroke 7.8% for DYNAMO-HIA vs 5.2% of CHD policy model). Thus, by
making approaches comparable we could not fully explain the variation between the models.
Obviously, there will be some remaining differences, such as the difference in demographic
and socio-economic data (such as country-specific incidence and prevalence of CVD). There-
fore, a comparative study of the various models using similar input data (demographic as well
as intervention scenario) could help to understand how the impact assessment differs between
the various models, taking into account the mutual differences between the models.
One aspect of interest since the completion of this analysis is the growing evidence of social
inequalities in salt consumption as the more disadvantaged social groups not only have the
highest burden of cardiovascular disease, but also the highest salt consumption [26–29]. A
reduction in salt intake would therefore be likely to exert a greater health impact in those
groups. Also, newer studies have been published that estimated the health impact of salt reduc-
tion (e.g. [30–33], using similar approaches. Therefore, we do not think that inclusion of these
papers will change our conclusions.
In conclusion, our study shows that especially differences in the strength and shape of the
dose-response association from salt to health contributed to heterogeneity of the health impact
estimates reported. We concluded that transparency of the models structures and (demo-
graphic) data used is essential to be able to interpret the outcomes of a health impact assess-
ment. We advise to develop standard reporting guidelines for the field of non-communicable
disease scenario modelling.
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